Growth induction of rat primary hepatocytes using antisense oligonucleotides

Area of Science:

• Hepatocyte biology
• Cell cycle regulation
• Molecular medicine

Background:

• Hepatocyte growth is tightly regulated by cell-cycle proteins.
• Understanding these regulatory mechanisms is crucial for liver regeneration and disease.
• Tumor suppressors (RB, p53) and CDK inhibitors (p21, p27) play key roles in cell cycle control.

Purpose of the Study:

• To investigate the role of antisense S-oligonucleotides in modulating cell-cycle-related proteins for hepatocyte growth control.
• To evaluate the growth-promoting effects of targeting retinoblastoma (RB) protein, p53, p21, and p27 in adult and fetal hepatocytes.
• To compare the efficacy of these antisense oligonucleotides with hepatocyte growth factor (HGF).

Main Methods:

• Utilized antisense S-oligonucleotides to suppress the expression of RB protein, p53, p21, and p27 in hepatocyte cultures.
• Measured protein expression levels following oligonucleotide treatment.
• Assessed hepatocyte proliferation using 3H-thymidine incorporation and DNA content analysis.
• Evaluated the synergistic effects of antisense oligonucleotides and HGF on hepatocyte growth.

Main Results:

• Antisense oligonucleotides significantly suppressed target protein expression in both adult and fetal hepatocytes at 2.5 microM.
• All tested antisense oligonucleotides demonstrated significant hepatocyte growth-promoting effects.
• The growth-promoting potential of antisense oligonucleotides was comparable or superior to HGF (10 ng/ml).
• HGF enhanced the growth-promoting effects of antisense oligonucleotides in both adult and fetal hepatocyte cultures.
• Growth promotion was also observed in suspension cultures, indicating broad applicability.

Conclusions:

• Targeting cell-cycle regulatory proteins with antisense S-oligonucleotides is an effective strategy for promoting hepatocyte growth.
• This approach offers a potential alternative or adjunct to HGF for liver regeneration therapies.
• Further research into oligonucleotide-based modulation of cell cycle proteins could advance treatments for liver diseases.